The Study About Physical Activity for Subjects with Prevention of Benign Prostate Hyperplasia

Overview

Journal Int Neurourol J

Date 2014 Oct 4

PMID 25279244

Citations 12

Authors

Ho Won Lee

Shin Ah Kim

Ji Won Nam

Mi Kyung Kim

Bo Youl Choi

Hong Sang Moon

Affiliations

Soon will be listed here.

Abstract

Purpose: The number of benign prostatic hyperplasia (BPH) subjects has been increasing worldwide, and many studies have been conducted to determine the treatment that can delay drug therapy or surgery. Subsequently, most of these studies involved physical activity (PA) and associated factors. Therefore, we aimed to determine factors associated with BPH prevalence based on a review of past and present studies and to investigate the effect of a healthy lifestyle as a protective factor of BPH occurrence.

Methods: We selected 582 subjects aged ≥40 years from an initial 779 subjects recruited from Gyeonggi, Yangpyeong, South Korea, during August 2009 to August 2011. Trained investigators surveyed International Prostate Symptom Score and demographic information, including PA and lifestyle questionnaire during face-to-face interviews; further, they performed digital rectal examination, rectal ultrasonography, and measured prostate-specific antigen levels. The statistical association between PA and BPH was analyzed by logistic regression analysis using multivariable regression models which use categorical variables by the Cochran-Mantel-Haenszel test and continuous variables by the general linear model.

Results: Seven statistically significant variables for PA were selected. Regular exercise, frequency of exercise, sedentary time, nonsedentary time, leisure time PA (metabolic equivalent, hr/wk) were not statistically associated with prostate volume but sedentary time (hr/day) was the only factor that showed a significant association in the multivariable model, including a linear effect relationship. Subjects with lower levels of sedentary time (4.5-7.0 hr/day) had a significantly lower risk of BPH (odds ratio [OR], 0.93; 95% confidence interval [CI], 0.52-1.67) than those with a higher sedentary time (>7 hr/day) (OR, 1.72; 95% CI, 0.96-3.09) (P for trend=0.05).

Conclusions: Our study showed that reducing sedentary time could have a protective effect and reduce the prevalence of BPH. Further prospective studies with a larger sample size are needed to assess the impact of reducing sedentary time on BPH risk.

Citing Articles

Global burden of benign prostatic hyperplasia in males aged 60-90 years from 1990 to 2019: results from the global burden of disease study 2019.

Ye Z, Wang J, Xiao Y, Luo J, Xu L, Chen Z BMC Urol. 2024; 24(1):193.

PMID: 39237966 PMC: 11376082. DOI: 10.1186/s12894-024-01582-w.

Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019.

Liu D, Li C, Li Y, Zhou L, Li J, Wang Y World J Urol. 2023; 41(12):3629-3634.

PMID: 37831157 DOI: 10.1007/s00345-023-04658-8.

Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study.

Wang Y, Yang L, Deng Y, Yan S, Luo L, Chen P J Transl Med. 2022; 20(1):495.

PMID: 36309747 PMC: 9617448. DOI: 10.1186/s12967-022-03722-y.

Factors associated with quality of life in patients with benign prostatic hyperplasia, 2009-2016.

Park S, Lee K, Choi M, Lee M Medicine (Baltimore). 2022; 101(36):e30091.

PMID: 36086750 PMC: 9512327. DOI: 10.1097/MD.0000000000030091.

Evaluation of the Therapeutic Effect of the Traditional Herbal Medicine and Gum on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats.

Akbari F, Azadbakht M, Gaurav A, Azimi F, Mahdizadeh Z, Vahedi L Adv Urol. 2022; 2022:5742431.

PMID: 35847835 PMC: 9277211. DOI: 10.1155/2022/5742431.

References

Meigs J, Mohr B, Barry M, Collins M, McKinlay J . Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001; 54(9):935-44. DOI: 10.1016/s0895-4356(01)00351-1. View

Gass R . Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int. 2002; 90(7):649-54. DOI: 10.1046/j.1464-410x.2002.03001.x. View

Brown D, Brown D, Heath G, Balluz L, Giles W, Ford E . Associations between physical activity dose and health-related quality of life. Med Sci Sports Exerc. 2004; 36(5):890-6. DOI: 10.1249/01.mss.0000126778.77049.76. View

Platz E, Kawachi I, Rimm E, Colditz G, Stampfer M, Willett W . Physical activity and benign prostatic hyperplasia. Arch Intern Med. 1998; 158(21):2349-56. DOI: 10.1001/archinte.158.21.2349. View

Giovannucci E, Rimm E, Chute C, Kawachi I, Colditz G, Stampfer M . Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994; 140(11):989-1002. DOI: 10.1093/oxfordjournals.aje.a117206. View

Caine M . The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986; 136(1):1-4. DOI: 10.1016/s0022-5347(17)44709-4. View

Parsons J, Im R . Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol. 2009; 182(4):1463-8. DOI: 10.1016/j.juro.2009.06.038. View

Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C . Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2014; 115(1):24-31. DOI: 10.1111/bju.12728. View

Parsons J . Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007; 178(2):395-401. DOI: 10.1016/j.juro.2007.03.103. View

10.

Irwin D, Kopp Z, Agatep B, Milsom I, Abrams P . Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011; 108(7):1132-8. DOI: 10.1111/j.1464-410X.2010.09993.x. View

11.

Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M . Benign prostatic hyperplasia: a new metabolic disease?. J Endocrinol Invest. 2014; 37(4):313-22. DOI: 10.1007/s40618-014-0051-3. View

12.

Hootman J . 2008 Physical Activity Guidelines for Americans: an opportunity for athletic trainers. J Athl Train. 2009; 44(1):5-6. PMC: 2627809. DOI: 10.4085/1062-6050-44.1.5. View

13.

McVary K . BPH: epidemiology and comorbidities. Am J Manag Care. 2006; 12(5 Suppl):S122-8. View

14.

Parsons J, Kashefi C . Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008; 53(6):1228-35. DOI: 10.1016/j.eururo.2008.02.019. View

15.

Groves H, Chang D, Palazzi K, Cohen S, Parsons J . The incidence of acute urinary retention secondary to BPH is increasing among California men. Prostate Cancer Prostatic Dis. 2013; 16(3):260-5. DOI: 10.1038/pcan.2013.11. View

16.

Hollingsworth J, Wilt T . Lower urinary tract symptoms in men. BMJ. 2014; 349:g4474. PMC: 4688452. DOI: 10.1136/bmj.g4474. View

17.

Lepor H . Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2006; 6 Suppl 9:S3-S10. PMC: 1472917. View

18.

Cui Y, Zong H, Yan H, Li N, Zhang Y . Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis. Urol Int. 2014; 93(2):152-9. DOI: 10.1159/000356272. View

19.

Sallis J, Haskell W, Wood P, Fortmann S, Rogers T, Blair S . Physical activity assessment methodology in the Five-City Project. Am J Epidemiol. 1985; 121(1):91-106. DOI: 10.1093/oxfordjournals.aje.a113987. View

20.

Schoenfeld M, Shortridge E, Gelwicks S, Cui Z, Wong D . Treatment patterns in alpha-blocker therapy for benign prostatic hyperplasia. Am J Mens Health. 2013; 8(3):267-72. DOI: 10.1177/1557988313510732. View